3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
9
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
pembrolizumab
24
Nivolumab
23
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Biopsy
7
dabrafenib
6
Surveys and Questionnaires
6
Dacarbazine
6
trametinib
5
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Blood Specimen Collection
5
Aminolevulinic Acid
5
sonidegib
4
encorafenib
4
Photochemotherapy
4
Mohs Surgery
4
HhAntag691
4
Educational Status
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
Decitabine
×
Dermatologic
×
Clear all
NCT00715793
2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2
Completed
39 enrolled
12 charts